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intention (5 with recurrent lung cancer, and 2 with metastasis from lung 
cancer). Platinum ﬁducials and intravascular embolisation coils were 
used as markers. In total, 180 markers were placed: 67 intrapulmonal 
in 26 patients (median: 3 markers per tumor), 84 intravascular in 28 
patients (median: 3 makers per tumor), 25 extrapulmonal in 5 patients 
(median: 5 makers per tumor), and 4 markers in 1 patient with the 
bronchoscopic method. Seven days after marker placement, a planning 
CTscan was made and the GTV was contoured on a 4-D CT scan. The 
PTV equaled the GTV plus 5 mm. For early stage lung cancer, a total 
dose of 36 to 60 Gy, (median dose: 60 Gy) was given in 3 fractions. 
Solitary metastasis to the lung were treated with a total dose of 45 to 60 
Gy (median dose: 45 Gy) in 3 to 5 fractions. For palliative treatment, a 
total dose of 30 to 49 Gy was given in 3-7 fractions (median dose: 40 
Gy). The dose to the PTV was prescribed to the 70-85% isodose line. 
The response was evaluated according to the RECIST criteria with a 
CT scan 6-8 weeks after the last treatment and routinely thereafter. The 
median follow up with CTscan was 6 months (range: 2-18).
Results: Six patients (11%) had a pneumothorax after intrapulmonal 
placement. One patient had no symptoms. A thorax drain was placed 
in the 5 other patients. One patient complained of severe intrathora-
cal pain several hours after intravascular coil placement and 5 patients 
complained of haemoptoe, one after the intravascular coil placement 
and 4 after the intrapulmonal placement.
The local control was 97%. Seven tumors had a complete response, 
38 tumors had a partial response, 13 tumors had stable disease and 2 
tumors (both early stage lung cancer) were progressive, one after 8 
months and the other after 15 months. 
Conclusion: Low toxicity of marker placement was seen due to the 
4 methods. CyberKnife tumor tracking with markers is feasible and 
resulted in excellent tumor response.
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Background: Local recurrence is a major problem after (chemo-)ra-
diation for NSCLC. We hypothesized that for each individual patient 
the highest therapeutic ratio could be achieved by increasing the total 
tumor dose (TTD) to the limits of the normal tissues, delivered within 
5 weeks. In a theoretical model this resulted in an increase in tumor 
control probability from approximately 5% for a classical scheme (60 
Gy in 6 weeks) to 25% for the study scheme. Here, we report the ﬁrst 
results of a prospective clinical trial.
Methods: Twenty-nine patients with medically inoperable (stage I, 
n=2) or locally advanced NSCLC (stage III, n=27), in a good general 
condition (WHO-PS 0-1) and with a reasonable lung function (FEV1 
>50% of predicted) were included. Most patients (25/29) received 
induction chemotherapy. All patients were irradiated using an individu-
alized prescribed TTD, based on normal tissue constraints (mean lung 
dose 19 Gy, maximal spinal cord dose 54 Gy, no constraints for esopha-
gus) up to a maximal TTD of 79.2 Gy. Radiotherapy was delivered in 
1.8 Gy fractions, twice daily. Acute and late (>3 months) toxicity was 
scored using the CTCAE-criteria. A FDG-PET-CT scan (n=27) was 
performed to evaluate (metabolic) response 70 days after radiotherapy 
according to EORTC-criteria (PET) and RECIST-criteria (CT). The 
Kaplan-Meier method was used to compute overall survival. 
Results: The mean delivered dose was 62.7 Gy (range 46.8-79.2 Gy). 
This corresponds to a mean biological equivalent dose of approxi-
mately 80 Gy (2 Gy fractions, once daily, in 8 weeks). Most patients 
experienced mild acute toxicity, while only 2 patients (6.8%) developed 
acute grade 3 toxicity (n=1 dysphagia, n=1 cough) as depicted in ﬁgure 
1. Concerning late toxicity, 93% of patients (n=25) showed radiograph-
ic changes (75% in <25% and 18% in >25% of the lungs), while 12 out 
of 28 patients (43%) had clinical symptoms (>gr 1 pneumonitis). One 
patient (3.4%) died 51 days after radiotherapy due pneumonitis (treat-
ment related mortality). 
The post-radiotherapy PET-CT showed in 18 patients a metabolic 
response (41% complete metabolic response, 26% partial metabolic 
response), whereas only in 9 patients (33.3%) a response was seen 
on CT (p=0.01). Eight patients (29.6%) showed progressive disease, 
consisting of loco-regional progression (n=4), metastases (n=3) or a 
combination of both (n=1). With a mean FU of 13 months the mean 
overall survival was 16.7 months and a 1-yr survival of 65%.
Conclusions: Personalized HI-CHART radiation prescription based on 
normal tissue constraints is tolerable and initial results are promising.
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Background: After a phase I trial of accelerated, twice daily high dose 
radiotherapy showing good tolerability, a prospective study relating 
primary tumor size with radiation dose in non-operated patients with 
NSCLC was started.
Methods: 01/2004 - 12/2006: 79 patients with 81 histologically / cy-
tologically proven NSCLC tumors. Stage I: 19 pts., II: 4 pts., IIIA: 31 
pts., IIIB: 25 pts. Weight loss >5% in the past 3 months: 20 patients. 
Slow planning CTs (4sec./slice), patients freely breathing, 7 mm 
margins GTV to PTV, target splitting technique. 4 groups with primary 
tumor sizes (mean number of 3 perpendicular diameters) <2,5; 2,5-4,5; 
4,5-6,0; >6,0 cm (11/41/22/7 pts., respectively); tumor dose 73,8; 79,2; 
84,6; 90,0 Gy (ICRU), respectively; single dose 1,8 Gy; twice daily, 
interval 11h; 5 days/week; duration 33 days median (29-42). Nodes 
61,2 Gy (54,0-75,6 Gy), nodes electively 45,0 Gy (to volume about 6 
cm cranial to macroscopically involved nodes). 
In 62 patients chemotherapy before RT was given, 2 cycles median (1-
10); no concurrent chemotherapy.
Median follow-up of patients alive: 16,1 months (4,2-40,1).
Results: Until now 10 local failures (0/11, 3/41, 5/22, 2/7 in the respec-
tive groups) and 2 regional failures, resulting in an actuarial local and 
regional tumor control of 77% and 96% at 2 years, respectively.
Overall actuarial 1-, 2-year survival rate for all patients: 75%, 55%, 
respectively, median 24,8 months. Median survival time for 28 patients 
IIIA-N2: 30,1 months.
2 patients suffered treatment-related letal acute toxicity: pulmonary ﬁ-
brosis 5 and 6 months after the end of radiotherapy. In the pretherapeu-
tic CT scans of both patients clear signs of existing pulmonary ﬁbrosis 
were visible. Furthermore no patient with acute pulmonary toxicity 
>grade 2. Acute esophagitis grade 3: 3 pts; grade 2: 4 pts.; grade1: 22 
pts. No chronic toxicity >grade1.
Conclusions: Local and regional tumor control rates are high. Nodes 
need smaller doses than primary tumors. Survival (considering a quar-
ter of the patients having unfavourable prognostic features) is good. 
Patients with preexisting pulmonary ﬁbrosis must be excluded from 
accelerated, twice daily applied high dose radiotherapy. Recruitment of 
patients to the study is continued.
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Background: The respiratory signal acquisition should be reliable for 
the gated radiotherapy. The spirometer has a direct correlation with a 
lung volume change but is susceptible to a signal drift. On the other 
hand, the surface displacement measurement is convenient and drift 
free but its amplitude can be affected by daily marker setup. In this 
work, a stable spirometer system was developed for the gated radio-
therapy and the correlation to an organ motion was obtained compared 
to that of a custom-made stereo camera system.
Methods: Tidal volume measurements were performed on a spirometer 
ampliﬁer and a ﬂow head. Spirometer calibration was performed using 
a 3L calibration syringe to convert the reading value from voltage to 
ﬂow rate and correct for different ﬂow sensitivity. A tidal volume signal 
was produced by integrating ﬂow rate by time. The volume baseline 
was determined in real time using the random sample consensus 
(RANSAC) algorithm to exclude the irregular breathing points. A skin 
surface marker was monitored by a stereo vision system. The marker 
imaging was performed at two IEEE-1394 cameras. The stereo-image 
pair of marker was acquired synchronously and the 3-D position was 
determined using the triangulation algorithm. Skin surface displace-
ment measurements were compared to the tidal volume signal for com-
parison. The ﬂuoroscopic image of lung tumor patients was correlated 
to the surrogate marker signals. 
Results: Respiratory signal was acquired and displayed by the 
developed software. The volume drift correction ensured the stable 
acquisition of respiratory signal which allowed for gating the linear 
accelerator. The stereo camera system could track the 3-D position of 
skin markers with an accuracy of 2 mm. The comparison of the two 
surrogate marker signals represented some phase delay and indicated 
that the spirometry had a better correlation with a real tumor motion 
than the surface displacement measurements.
Conclusions: The respiratory signal acquisition system was developed 
using the spirometer and the stereo-vision camera for gated radiothera-
py. Stable spirometry volume signal could be attained for the amplitude 
gating by applying the user-deﬁned correction algorithm. The devel-
oped system was useful to investigate the accuracy of surrogate marker 
signals and their correlation to a real tumor motion.
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Purpose: To evaluate the treatment outcomes of body-frame based 
fractionated stereotactic radiosurgery (SRS) on consecutive days for 
stage I non-small cell lung cancer (NSCLC).
Materials: Between Jun 1999 to Feb 2006, 34 patients diagnosed as 
stage I, T1N0 or T2N0, resectable NSCLC were treated with body-
frame based fractionated SRS. The reasons of curative SRS were 
variable. Twenty-ﬁve patients had several medical problems conﬂicting 
surgical procedure and the other nine patients refused surgery although 
they could be a surgical candidate. To obtain higher tumor dose and 
better dose conformation with less normal tissue toxicity, we used 
fractionated stereotactic radiosurgery (SRS) on consecutive 3-4 days. 
Doses of 10-20 Gy per fraction were delivered to the clinical target vol-
ume (CTV) up to a total dose of 30-60 Gy with three to four fractions 
on consecutive days.
Results: Ten patients (29.4%) showed a complete response, 19 (55.9%) 
a partial response, and 5 patients (14.7%) showed stable disease, result-
ing in a total response rate of 85.3%. One patient (4%) showed progres-
sive disease 1 month after SRS. The overall local progression free 
